This study is comparing surgery to remove part or all of a kidney (partial or total nephrectomy) to surgery plus the drug nivolumab (Opdivo®), to treat patients with kidney cancer that has not spread to other parts of the body (is localized) or has spread outside the kidney (metastasized) but have 3 or fewer metastases (except liver or bone metastases) that are resectable or can be managed by thermal ablation or radiation. Nivolumab in an immuno-oncology drug and may interfere with the ability of tumour cells to grow and spread. Giving nivolumab before a nephrectomy may make the tumour smaller and reduce the amount of normal tissue that needs to be removed. In this study, nivolumab will also be given after the nephrectomy to see if it increases a patient’s chances for survival. It is not yet known whether the combination of nivolumab and nephrectomy works better than nephrectomy only in treating patients with kidney cancer. This trial is for patients who are newly diagnosed with kidney cancer and have a high risk of their cancer coming back. Patients can have clear cell, sarcomatoid or unknown (unclassified) types of kidney cancer. One group of patients will be given nivolumab before and after their surgery. The other group of patients will have surgery followed by close observation (active surveillance). This study is not for patients with advanced kidney cancer, whose cancer has spread beyond the kidney (metastasized).
|Hospital / Cancer Centre||Principal Investigator||Location||Trial Status|
|Hospital / Cancer CentreTom Baker Cancer Centre||Principal InvestigatorDr Daniel Heng||LocationCalgary, AB||Trial StatusPending|
|Hospital / Cancer CentreJuravinski Cancer Centre||Principal InvestigatorDr Anil Kapoor||LocationHamilton, ON||Trial StatusPending|
|Hospital / Cancer CentreSt. Joseph's - McMaster Institute of Urology||Principal InvestigatorDr Anil Kapoor||LocationHamilton, ON||Trial StatusPending|